Hodgkin Lenfoma
Özet
Hodgkin lenfoma , modern tedavi yaklaşımlarıyla yüksek başarı oranlarına ulaşan, büyük ölçüde tedavi edilebilir bir hastalık haline gelmiştir. Ancak, tedavi sonrası uzun dönem sağ kalan hastalarda ikincil kanserler, kardiyovasküler hastalıklar, pulmoner toksisite, endokrin bozukluklar ve kısırlık gibi geç komplikasyonlar önemli bir sorun teşkil etmektedir. Bu etkiler, hastaların yaşam kalitesini düşürebilmekte ve düzenli takip gerektirmektedir. Erken dönemde nüks ise genellikle ilk 5 yıl içinde görülmekte ve nükslerin %50’sinden fazlası hastanın kendi bildirdiği semptomlar sayesinde tespit edilmektedir. Bu dönemde hasta hikayesi, fiziksel muayene ve gerekirse görüntüleme yöntemleri kritik rol oynar. Tedavi sonrası dönemde yapılan pozitron emisyon tomografisi/bilgisayarlı tomografi (PET/BT) taramaları, özellikle aktif hastalığın erken tespiti açısından önemlidir ancak rutin kullanım yerine klinik ihtiyaç doğrultusunda uygulanması önerilmektedir. Geç komplikasyonlar arasında en sık görülenler ikincil kanserlerdir. Genç yaşta göğüs ışınlaması yapılan kadınlarda meme kanseri riski, sigara kullanımı ve radyoterapi ile artan akciğer kanseri riski gibi durumlar bu grupta dikkatle izlenmelidir. Kardiyovasküler komplikasyonlar ise mediastinal radyoterapi ve antrasiklin bazlı kemoterapilere bağlı olarak sıkça görülmekte; miyokard enfarktüsü ve kapak hastalıkları gibi ciddi sorunlara yol açmaktadır.
Tedavi sonrası izlemde, bireyselleştirilmiş takip stratejileri benimsenmelidir. Meme kanseri riski yüksek kadınlarda mamografi ve magnetik rezonans görüntüleme (MRI) ile tarama yapılmalı, akciğer kanseri riski taşıyan hastalarda düşük doz bilgisayarlı tomografi tercih edilmelidir. Kardiyovasküler hastalıklar açısından elektrokardiyogram (EKG), ekokardiyografi ve koroner arter kalsiyum skoru gibi yöntemlerle düzenli değerlendirme yapılmalıdır. Sonuç olarak, Hodgkin lenfoma tedavisinden sağ kurtulan hastalarda erken dönemde nükslerin tespiti ve geç komplikasyonların yönetimi multidisipliner bir yaklaşımla ele alınmalıdır. Daha az toksik tedavi rejimlerinin geliştirilmesi, bireyselleştirilmiş izlem protokolleri ve erken teşhis stratejileri, bu hasta grubunun uzun dönem yaşam kalitesini artırmada kritik rol oynamaktadır.
Hodgkin lymphoma has become a highly treatable disease with modern therapeutic approaches achieving high success rates. However, long-term survivors are at significant risk of late complications, including secondary cancers, cardiovascular diseases, pulmonary toxicity, endocrine disorders, and infertility. These complications can substantially affect patients’ quality of life, necessitating regular follow-up. Early relapse typically occurs within the first five years, with over 50% of cases detected through patient-reported symptoms. During this period, patient history, physical examination, and, if needed, imaging methods play a critical role. Post-treatment positron emission tomography/computed tomography (PET/CT) scans are particularly valuable for the early detection of active disease but should be utilized based on clinical necessity rather than routine practice.Among late complications, secondary cancers are the most common. Young women who have undergone chest irradiation are at increased risk of breast cancer, while lung cancer risk is elevated due to smoking and radiotherapy exposure. Cardiovascular complications, frequently linked to mediastinal radiotherapy and anthracycline-based chemotherapy, include severe conditions such as myocardial infarction and valvular diseases.
Post-treatment follow-up should adopt individualized monitoring strategies. Women at high risk for breast cancer should undergo screening with mammography and magnetic resonance imaging (MRI), while low-dose computed tomography is recommended for patients at risk of lung cancer. Cardiovascular health should be regularly assessed using electrocardiograms (ECG), echocardiography, and coronary artery calcium scoring. In conclusion, the detection of early relapses and the management of late complications in Hodgkin lymphoma survivors should be approached through a multidisciplinary strategy. The development of less toxic treatment regimens, personalized follow-up protocols, and early diagnostic strategies play a crucial role in improving the long-term quality of life for this patient population.
Referanslar
Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022;36:1720-1748. doi: 10.1038/s41375-022-01620-2 .
Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. IARC Press: Lyon 2017.
Campo E, Jaffe ES, Cook JR, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood 2022; 140:1229-1253. doi: 10.1182/blood.2022015851.
NCCN. Clinical Practice Guidelines in Oncology. Version 4.2024 — October 22, 2024. Hodgkin Lymphoma. www.nccn.org [online]
Carbone PP, Kaplan HS, Musshoff K, et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Research 1971;31:1860-1861.
Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. Journal of Clinical Oncology 2014;32:3059-3068. doi: 10.1200/JCO.2013.54.8800.
Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. The New England journal of medicine 1998;339:1506-1514. doi: 10.1056/NEJM199811193392104.
Moccia AA, Donaldson J, Chhanabhai M, et al. International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era. Journal of Clinical Oncology 2012;30:3383-3388. doi: 10.1200/JCO.2011.41.0910.
Cheson BD. Role of functional imaging in the management of lymphoma. Journal of Clinical Oncology 2011;29:1844-1854. doi: 10.1200/JCO.2010.32.5225.
Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. Journal of Clinical Oncology 2014;32:3048-3058. doi: 10.1200/JCO.2013.53.5229.
Aldin A, Umlauff L, Estcourt LJ, et al. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies. Cochrane Database of Systematic Review 2019;9:CD012643. doi: 10.1002/14651858.CD012643.
Kobe C, Goergen H, Baues C, et al. Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma. Blood 2018;132:2273-2279 . doi: 10.1182/blood-2018-05-852129.
Podoloff DA, Advani RH, Allred C, et al. NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. Journal of the National Comprehensive Cancer Network 2007;5 Suppl 1:S1-S22; quiz S23-22
El-Galaly TC, d'Amore F, Mylam KJ, et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. Journal of Clinical Oncology 2012;30:4508-4514. doi: 10.1200/JCO.2012.42.4036
Moulin-Romsee G, Hindie E, Cuenca X, et al. (18)F-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. European Journal of Nuclear Medicine and Molecular Imaging 2010;37:1095-1105. doi: 10.1007/s00259-009-1377-5.
Engert A, Franklin J, Eich HT et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin’s lymphoma: final results of the GHSG HD7 trial. Journal of Clinical Oncology 2007; 25: 3495–3502(ESMO 4). doi: 10.1200/JCO.2006.07.0482.
Ferme´ C, Eghbali H, Meerwaldt JH et al. Chemotherapy plus involvedfield radiation in early-stage Hodgkin’s disease.The New England journal of medicine 2007; 357: 1916–1927(ESMO 5). doi: 10.1056/NEJMoa064601.
Engert A, Haverkamp H, Kobe C et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 noninferiority trial. The Lancet 2012; 379: 1791–1799. 15. doi: 10.1016/S0140-6736(11)61940-5.
Borchmann P, Goergen H, Kobe C et al. PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. The Lancet 2017; 390: 2790–2802. doi: 10.1016/S0140-6736(17)32134-7.
Schmitz N, Pfistner B, Sextro M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. The Lancet 2002; 359: 2065–2071. doi: 10.1016/S0140-6736(02)08938-9.
Sibon D, Morschhauser F, Resche-Rigon M et al. Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group. Haematologica 2016; 101: 474–481. doi: 10.3324/haematol.2015.136408.
Moskowitz CH, Nademanee A, Masszi T et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.The Lancet 2015; 385: 1853–1862. doi: 10.1016/S0140-6736(15)60165-9.
Eichenauer DA, Plu¨tschow A, Fuchs M et al. Long-term course of patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Journal of Clinical Oncology 2015; 33: 2857–2862. doi: 10.1200/JCO.2014.60.4363.
Nogova´ L, Reineke T, Brillant C et al. Lymphocyte-predominant and classical Hodgkin’s lymphoma: a comprehensive analysis from the German Hodgkin Study Group. Journal of Clinical Oncology 2008; 26: 434–439. doi: 10.1200/JCO.2007.11.8869.
Eichenauer DA, Pluetschow A, Schroeder L et al. Relapsed nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group (GHSG). Blood 2016; 128: 922. doi: 10.1182/blood-2018-02-83643
Mauch P, Ng A, Aleman B, et al. Report from the Rockefellar Foundation Sponsored International Workshop on reducing mortality and improving quality of life in long-term survivors of Hodgkin's disease: July 9-16, 2003, Bellagio, Italy. European Journal of Haematology Supplement 2005:68-76. DOI: 10.1111/j.1600-0609.2005.00458.x
Lynch RC, Sundaram V, Desai M, et al. Utility of routine surveillance laboratory testing in detecting relapse in patients with classic Hodgkin lymphoma in first remission: Results from a large single-institution study. JCO Oncology Practice 2020;16:e902-e911. DOI: 10.1200/JOP.19.00733
D. A. Eichenauer, B. M. P. Aleman, M. Andre´ et al. Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2018 Oct 1;29(Suppl 4):iv19-iv29. doi: 10.1093/annonc/mdy080.
Ng A, Constine LS, Advani R, et al. ACR Appropriateness Criteria: follow-up of Hodgkin's lymphoma. Current Problems in Cancer 2010;34:211-227. doi: 10.1016/j.currproblcancer.2010.04.007.
Franklin J, Pluetschow A, Paus M, et al. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Annals of Oncology 2006;17:1749-1760. doi:10.1093/annonc/mdl302.
Swerdlow AJ, Higgins CD, Smith P, et al. Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study. Journal of Clinical Oncology 2011;29:4096-4104. doi: 10.1200/JCO.2011.34.8268
Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. Journal of the National Cancer Institute 2002;94:182-192. doi: 10.1093/jnci/94.3.182
Schaapveld M, Aleman BM, van Eggermond AM, et al. Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma. The New England Journal of medicine 2015;373:2499-2511 doi: 10.1056/NEJMoa1505949
van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. Journal of the National Cancer Institute 1995;87:1530-1537. doi: 10.1093/jnci/87.20.1530.
Travis LB, Hill D, Dores GM, et al: Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. Journal of the National Cancer Institute 97:1428-1437, 2005. doi: 10.1093/jnci/dji290.
Metcalfe K, Lubinski J, Lynch HT, et al: Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations. Journal of the National Cancer Institute 102:1874-1878, 2010. doi: 10.1093/jnci/djq443.
Leach MO, Boggis CR, Dixon AK, et al: Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: A prospective multicentre cohort study (MARIBS).The Lancet 365:1769-1778, 2005 14. doi: 10.1016/S0140-6736(05)66481-1.
Warner E, Hill K, Causer P, et al: Prospective study of ofbreast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. Journal of Clinical Oncology 29:1664-1669, 2011. doi: 10.1200/JCO.2009.27.0835
Ng AK, Garber JE, Diller LR, et al. Prospective study of the efficacy of breast magnetic resonance imaging and mammographic screening in survivors of Hodgkin lymphoma. Journal of Clinical Oncology 2013;31:2282-2288. doi: 10.1200/JCO.2012.46.5732.
Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA: a Cancer Journal for Clinicians 2007;57:75-89. doi: 10.3322/canjclin.57.2.75.
American Cancer Society guidelines for the early detection of cancer. 2023. cancer.org 1.800.227.2345
Oliva S, Puzzovivo A, Gerardi C, et al. Late Cardiological Sequelae and Long-Term Monitoring in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Systematic Review by the Fondazione Italiana Linfomi. Cancers (Basel) 2021;14. doi: 10.3390/cancers14010061
Heidenreich PA, Hancock SL, Lee BK, et al. Asymptomatic cardiac disease following mediastinal irradiation. Journal of the American College of Cardiology 2003;42:743-749. doi: 10.1016/s0735-1097(03)00759-9.
Adams MJ, Lipsitz SR, Colan SD, et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. Journal of Clinical Oncology 2004;22:3139-3148. doi: 10.1200/JCO.2004.09.109.
Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007;109:1878-1886. doi: 10.1182/blood-2006-07-034405.
Girinsky T, M'Kacher R, Lessard N, et al. Prospective coronary heart disease screening in asymptomatic Hodgkin lymphoma patients using coronary computed tomography angiography: results and risk factor analysis. International Journal of Radiation Oncology biology physics. doi: 10.1016/j.ijrobp.2014.01.021.
Küpeli S, Hazirolan T, Varan A et al. evaluation of coronary artery disease by computed tomography angiography in patients treated for childhood Hodgkin's lymphoma Journal of clinical . 2010 Feb 20;28(6):1025-30. doi: 10.1200/JCO.2009.25.2627.
Centers for Disease Control and Prevention vaccine information for Adults 2021. Available at: https://www.cdc.gov/vaccines/adults/index.html
Behringer K, Breuer K, Reineke T, et al. Secondary amenorrhea after Hodgkin’s lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodg kin’s LymphomaStudyGroup.Journal of Clinical Oncology 2005;23(30): 7555 7564. doi: 10.1200/JCO.2005.08.138.
Howell S, Shalet S. Gonadal damage from chemotherapy and radiotherapy. Endocrinology and Metabolism Clinics of North America 1998; 27(4): 927–943. doi: 10.1016/s0889-8529(05)70048-7.
Franchi-Rezgui P, Rousselot P, Espie M, et al. Fertility in young women after chemotherapy with alkylating agents for Hodgkin and non-Hodgkin lymphomas.The Hematology Journal 2003; 4(2): 116–120. doi: 10.1038/sj.thj.6200248
Anselmo AP, Cartoni C, Bellantuono P, Maurizi-Enrici R, Aboulkair N, Ermini M. Risk of infertility in patients with Hodgkin’s disease treated with ABVD vs MOPP vs ABVD/ MOPP. Haematologica 1990; 75(2): 155–158
Heikens J, Behrendt H, Adriaanse R, Berghout A. Irreversible gonadal damage in male survivors of pediatric Hodgkin’s dis ease. Cancer 1996; 78(9): 2020–2024. doi: 10.1002/(sici)1097-0142(19961101)78:9<2020::aid-cncr25>3.0.co;2-y.
van der Kaaij MA, Heutte N, Le Stang N, et al. Gonadal function in males after chemotherapy for early-stage Hodgkin's lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Etude des Lymphomes de l'Adulte. Journal of Clinical Oncology 2007;25:2825-2832. doi: 10.1200/JCO.2006.10.2020. Epub 2007 May 21.
(199).. Hodgson DC, Pintilie M, Gitterman L, et al. Fertility among female hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy. Hematological Oncology 2007;25:11-15. doi: 10.1002/hon.802
Hodgson DC, Pintilie M, Gitterman L, et al. Fertility among female hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy. Hematological Oncology 2007;25:11-15. doi: 10.1200/JCO.2005.02.7243
Boleti E, Mead GM. ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors. Annals of Oncology 2007;18:376-380. doi: 10.1093/annonc/mdl397
Evens AM, Cilley J, Ortiz T, et al. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. British Journal of Haematology 2007;137:545-552. doi: 10.1111/j.1365-2141.2007.06598.x
